Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas.
暂无分享,去创建一个
Leland S. Hu | Susan M. Chang | B. Rosen | M. Gilbert | B. Erickson | Jayashree Kalpathy-Cramer | P. Wen | J. Boxerman | M. J. van den Bent | M. Weller | T. Cloughesy | L. Shankar | W. Wick | K. Schmainda | D. Barboriak | E. Gerstner | E. Galanis | T. Kaufmann | M. Smits | C. Quarles | B. Ellingson | C. Chung | A. Musella | P. Jacobs | Raymond Huang | W. K. Al Yung | David F. Arons | A. Kingston | David Sandak | Max Wallace | C. Haynes
[1] J. Boxerman,et al. Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low–Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors , 2019, American Journal of Neuroradiology.
[2] Thomas E. Yankeelov,et al. Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO) , 2019, Tomography.
[3] J. Boxerman,et al. Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object , 2018, American Journal of Neuroradiology.
[4] P. Bogner,et al. Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas , 2018, Magnetic resonance in medicine.
[5] B Erickson,et al. Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project , 2018, American Journal of Neuroradiology.
[6] Benjamin M Ellingson,et al. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma , 2017, American journal of clinical oncology.
[7] Natenael B. Semmineh,et al. A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials , 2017, Tomography.
[8] J. Boxerman,et al. Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas , 2017, American Journal of Neuroradiology.
[9] Diana Delgado,et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis , 2017, Neuro-oncology.
[10] Wade M Mueller,et al. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics , 2017, Journal of Neuro-Oncology.
[11] Eric S. Paulson,et al. Spiral Perfusion Imaging With Consecutive Echoes (SPICE™) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility , 2016, Tomography.
[12] J. Boxerman,et al. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)‐MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab , 2016, Journal of magnetic resonance imaging : JMRI.
[13] Ashley M Stokes,et al. Assessment of a simplified spin and gradient echo (sSAGE) approach for human brain tumor perfusion imaging. , 2016, Magnetic resonance imaging.
[14] J L Boxerman,et al. Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange , 2016, American Journal of Neuroradiology.
[15] D. Mankoff,et al. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI , 2016, Clinical Cancer Research.
[16] B. Erickson,et al. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma , 2015, American Journal of Neuroradiology.
[17] Jingping Xie,et al. Assessing tumor cytoarchitecture using multiecho DSC‐MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE) , 2015, Magnetic resonance in medicine.
[18] Marion Smits,et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.
[19] J. Kalpathy-Cramer,et al. Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma , 2015, American Journal of Neuroradiology.
[20] S. Heiland,et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. , 2015, Neuro-Oncology.
[21] A Gregory Sorensen,et al. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. , 2015, Neuro-oncology.
[22] David Bonekamp,et al. Association of overall survival in patients with newly diagnosed glioblastoma with contrast‐enhanced perfusion MRI: Comparison of intraindividually matched T1‐ and T2*‐based bolus techniques , 2015, Journal of magnetic resonance imaging : JMRI.
[23] M Wintermark,et al. ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain , 2015, American Journal of Neuroradiology.
[24] A. Omuro,et al. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence , 2015, American Journal of Neuroradiology.
[25] T. Cloughesy,et al. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab , 2015, Journal of Neuro-Oncology.
[26] E. Melhem,et al. Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas , 2015, European Radiology.
[27] T. Cloughesy,et al. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab , 2014, Cancer Imaging.
[28] W. Mueller,et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.
[29] Namkug Kim,et al. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. , 2014, Radiology.
[30] D. Aquino,et al. Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan , 2014, PloS one.
[31] P. Marsden,et al. Angiogenesis in glioblastoma. , 2013, The New England journal of medicine.
[32] Fernando Calamante,et al. The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI , 2013, NMR in biomedicine.
[33] Timothy A. Chan,et al. MRI perfusion in determining pseudoprogression in patients with glioblastoma. , 2013, Clinical imaging.
[34] G. Zaharchuk,et al. Combined spin‐ and gradient‐echo perfusion‐weighted imaging , 2012, Magnetic resonance in medicine.
[35] Benjamin M Ellingson,et al. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)‐MRI estimates of cerebral blood volume (CBV) in human gliomas , 2012, Journal of magnetic resonance imaging : JMRI.
[36] J. Boxerman,et al. The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard , 2012, American Journal of Neuroradiology.
[37] Leland S. Hu,et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival , 2012, Neuro-oncology.
[38] J. Debbins,et al. Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma , 2012, American Journal of Neuroradiology.
[39] J. Burdette,et al. Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study , 2011, American Journal of Neuroradiology.
[40] Xin Li,et al. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. , 2011, Radiology.
[41] Kim Mouridsen,et al. T1- and T*2-Dominant Extravasation Correction in DSC-MRI: Part I—Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[42] D. Hammoud,et al. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. , 2011, Neuro-oncology.
[43] D. Hoffmann,et al. Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study. , 2011, Journal of neuroradiology. Journal de neuroradiologie.
[44] D. Kong,et al. Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.
[45] K. Schmainda,et al. Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter‐ and intrapatient comparisons , 2010, Magnetic resonance in medicine.
[46] Jianhui Zhong,et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. , 2010, Radiology.
[47] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Ru-Fang Yeh,et al. Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. , 2010, Radiology.
[49] J. Debbins,et al. Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas , 2010, American Journal of Neuroradiology.
[50] M. Berger,et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2009, Radiology.
[51] M. J. van den Bent,et al. Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.
[52] T E Yankeelov,et al. A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation , 2009, Physics in medicine and biology.
[53] Ronald L. Wolf,et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. , 2009, Radiology.
[54] J E Heiserman,et al. Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.
[55] K. Schmainda,et al. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.
[56] R M Weisskoff,et al. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.
[57] Glyn Johnson,et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.
[58] B. D. Ward,et al. Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation , 2005, Magnetic resonance in medicine.
[59] H. Inoue,et al. Three-dimensional observations on microvascular growth in rat glioma using a vascular casting method , 2005, Journal of Cancer Research and Clinical Oncology.
[60] B. D. Ward,et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. , 2004, AJNR. American journal of neuroradiology.
[61] F Ståhlberg,et al. Effects of echo time variation on perfusion assessment using dynamic susceptibility contrast MR imaging at 3 tesla. , 2004, Magnetic resonance imaging.
[62] Linda Knutsson,et al. Aspects on the accuracy of cerebral perfusion parameters obtained by dynamic susceptibility contrast MRI: a simulation study. , 2004, Magnetic resonance imaging.
[63] A. Pathak,et al. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. , 2003, Neuro-oncology.
[64] R. Frayne,et al. Signal‐to‐noise ratio effects in quantitative cerebral perfusion using dynamic susceptibility contrast agents , 2003, Magnetic resonance in medicine.
[65] Glyn Johnson,et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. , 2002, Radiology.
[66] M. Takahashi,et al. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. , 2001, AJNR. American journal of neuroradiology.
[67] M A Viergever,et al. Simultaneous quantitative cerebral perfusion and Gd‐DTPA extravasation measurement with dual‐echo dynamic susceptibility contrast MRI , 2000, Magnetic resonance in medicine.
[68] A P Pathak,et al. Utility of simultaneously acquired gradient‐echo and spin‐echo cerebral blood volume and morphology maps in brain tumor patients , 2000, Magnetic resonance in medicine.
[69] B. Rosen,et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[70] B. Rosen,et al. Signal‐to‐noise analysis of cerebral blood volume maps from dynamic NMR imaging studies , 1997, Journal of magnetic resonance imaging : JMRI.
[71] B. Rosen,et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis , 1996, Magnetic resonance in medicine.
[72] B R Rosen,et al. Mr contrast due to intravascular magnetic susceptibility perturbations , 1995, Magnetic resonance in medicine.
[73] W. J. Lorenz,et al. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. , 1994, Radiology.
[74] B. Rosen,et al. Microscopic susceptibility variation and transverse relaxation: Theory and experiment , 1994, Magnetic resonance in medicine.
[75] E F Halpern,et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.
[76] T Kubota,et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. , 1993, Radiology.
[77] B. Rosen,et al. Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.
[78] B. Rosen,et al. MR Contrast Due to Microscopically Heterogeneous Magnetic Susceptibility: Numerical Simulations and Applications to Cerebral Physiology , 1991, Magnetic resonance in medicine.
[79] Society of magnetic resonance in medicine , 1990 .
[80] B. Rosen,et al. Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.
[81] B. Rosen,et al. Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects , 1988, Magnetic resonance in medicine.
[82] K. Zierler,et al. On the theory of the indicator-dilution method for measurement of blood flow and volume. , 1954, Journal of applied physiology.